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Case report
Symptoms of delusion: the eﬀects of
discontinuation of low-dose venlafaxine
Introduction
Venlafaxine, a serotonin-norepinephrine reuptake
inhibitor, is known to carry a risk of discontinu-
ation syndrome due to its relatively short half-life.
The frequency of discontinuation syndrome was
reported to increase with higher doses and abrupt
discontinuation. The common symptoms are physi-
cal, including dizziness, headaches and nausea, as
well as psychiatric symptoms such as agitation and
anxiety (1, 2). Conversely, reports of psychotic
symptoms have been few (2). We report a patient
who experienced psychotic and physical symptoms
during gradual discontinuation of low-dose venla-
faxine while being administered clomipramine.
That combination of symptoms ﬁts the diagnostic
criteria for discontinuation syndrome and required
long-term antipsychotic treatment until resolution.
Case report
A 31-year-old woman with major depression came
to our out-patient clinic after having lived abroad.
She had no prior history of physical illness,
delusional symptoms, manic episodes or substance
abuse. Before moving abroad, she had suﬀered
from mild depressive mood, slight anxiety and low
self-conﬁdence for the ﬁrst time, and had been
treated for about 1 year with clomipramine
(20–40 mg ⁄day).She fully recovered and safely
stopped medication (i.e. she experienced no
discontinuation syndrome) 2 months before
leaving Japan. Within 6 months after going
abroad, she had a recurrence, was treated with
venlafaxine for 6 months and almost recovered on
a dosage of 37.5 mg ⁄day before returning to
Japan. When we ﬁrst saw her she exhibited a
slight depressive mood. Since venlafaxine is not
available in Japan, we decided to start her on
another antidepressant and gradually discontinue
venlafaxine. We began coadministration of
20 mg ⁄day of clomipramine, which she had previ-
ously taken and had been safe and eﬀective for her
condition, and her regular venlafaxine dosage of
37.5 mg ⁄day. Her symptoms subsided after
5 weeks, so we reduced venlafaxine from 37.5 to
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32918.75 mg ⁄day and uptitrated clomipramine from
20 to 40 mg ⁄day. Since the imipramine equivalent
doses of venlafaxine and clomipramine are the
same (3), the decrease in the venlafaxine dosage
was almost exactly compensated by the increase in
the clomipramine dosage. Unfortunately, 4 days
later, she began to suﬀer from depressive mood
and delusions of reference along with palpitations
and nausea. Therefore, we increased the clomipr-
amine to 60 mg ⁄day. Two weeks later her depres-
sive mood and physical symptoms had recovered,
but she still exhibited some slight indications of
delusional feelings.
The patients condition remained stable until
her supply of venlafaxine ran out 8 weeks later,
and deterioration was seen within 4 days. She
lapsed back into delusions of persecution and
fear of death along with palpitations, dizziness,
nausea and stomachache that rendered her unable
to work. At this stage, because we were unable
to resume venlafaxine, we decided to administer an
antipsychotic agent, perospirone, which is a type
of serotonin dopamine antagonist available only
in Japan (4). The dosage was 8 mg ⁄day at the
beginning. After 5 weeks her symptoms began to
show visible improvement. It took a further
3 months of this antipsychotic treatment for her
to gradually recover from her symptoms and be
able to work in the same capacity as before.
Meanwhile, perospirone was tapered down to
4m g⁄day and ﬁnally 2 mg ⁄day in the last month
and discontinued. Twelve months have now passed
since then, and the patient has completely recov-
ered and shows no signs of any depressive mood or
delusional symptoms on the current clomipramine
dosage of 60 mg ⁄day.
Discussion
Our case is characterized by several signiﬁcant
ﬁndings. First, the patient exhibited prolonged
delusional symptoms and fear of death as well as
palpitations and nausea after discontinuation of
venlafaxine. Her condition was diagnosed as
venlafaxine discontinuation syndrome because
she experienced not only psychotic symptoms
but also physical symptoms (5). Second, she
experienced these symptoms during gradual dis-
continuation of an extremely low dosage of
venlafaxine combined with clomipramine, and
they ﬁnally required long-term antipsychotic
treatment. We speculate that the following factors
contributed to the manifestation of the symptoms
in this patient.
First, the symptoms may have resulted from an
interaction between venlafaxine remaining in her
system and clomipramine. In vitro studies indicate
that venlafaxine is a relatively weak inhibitor of
cytochrome P450 (CYP) 2D6 (1), and clomipr-
amine is metabolized by CYP 1A2, 2C, 2D6 and
3A4 (6). Therefore, some changes in clomipramine
metabolism may have been caused by adding or
stopping venlafaxine, leading to some adverse
reactions. A study of eight patients by Gomez and
Perramon showed that, when venlafaxine was
added to clomipramine, none of the patients
experienced any adverse reactions (one showed an
increase in the serum clomipramine level, but the
others did not) (7). Meanwhile, Benazzi reported a
patient who developed severe anticholinergic
adverse reactions and hand tremors when clomipr-
amine was augmented with venlafaxine (data on the
serum clomipramine level were not reported) (8).
Another patient experienced no adverse reactions
and no change in the serum clomipramine level
uponstopping venlafaxine (8). Although the data in
those case studies were somewhat limited and we
were unable to determine our patients serum
clomipramine level, we speculate that there might
have been an interaction between the two drugs in
our patient. Furthermore, the sensitivity to adverse
reactions to drugs diﬀers among individuals.
Another possibility may be that our patient had
intolerance to the discontinuation of low-dose
venlafaxine.Sheexperiencedpsychoticandphysical
symptoms not only when the dosage of venlafaxine
was decreased from 37.5 mg ⁄day to 18.75 mg ⁄day,
but also when 18.75 mg ⁄day of venlafaxine was
discontinued. Clomipramine was being coadminis-
tered with venlafaxine at both times, but the
clomipramine dose remained unchanged in the
second case. Given the stable dosage of clomipr-
amine when venlafaxine was discontinued, it would
seem that the symptoms that occurred were a result
of the gradual discontinuation of the low-dose
venlafaxine, although, as noted above, there may
have been interaction between venlafaxine remain-
ing in her system and clomipramine. It was reported
that patients generally experience discontinuation
syndrome upon stopping higher dosages of venla-
faxine (2). However, there have been reports that in
discontinuation syndrome associated with low-dose
venlafaxine certain patients developed severe psy-
chotic symptoms, as was the case with our patient.
Louie et al. (9) reported a 46-year-old woman who
experienced auditory hallucinations 3 days after
reducingthevenlafaxinedosage(from37.5 mgb.i.d.
for 10 days to 18.75 mg b.i.d.). The symptoms
persisted until her venlafaxine dosage was increased
to 56.25 mg ⁄day. Regarding combination therapy,
Parker and Blennerhassett (10) reported a 42-year-
old man who had auditory hallucinations for a
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75-mg ⁄day venlafaxine combined with
1000 mg ⁄day lithium. Fava (11) described a 59-
year-old man with bipolar disorder (type 1) who
manifested manic symptoms after venlafaxine
(37.5 mg ⁄day) was discontinued and replaced with
lithium. The symptoms resolved within a few days
after venlafaxine was restarted at 37.5 mg ⁄day.
Venlafaxine was discontinued after 3 months, and
thepatientagainexperienceddiscontinuationsymp-
toms, which subsided within 2 weeks. All of the
above patients also experienced physical symptoms.
Webelievethatdiscontinuationofthelowdosage
of venlafaxine played a signiﬁcant role in these
symptoms.Onepossibleexplanationforthesesymp-
toms is the serotonin reuptake inhibitor (SRI)-like
eﬀectsofvenlafaxineatlowdosages.Itwasreported
that,likeotherSRIs,venlafaxineselectivelyinhibited
5-HT uptake at low dosages (12), while others
reported that discontinuation of SRIs resulted in a
rapid decrease in serotonin availability in the brain
(13).Thisaccountsforthemanifestationnotonlyof
physical symptoms such as dizziness and intestinal
symptoms, but also of psychiatric symptoms. It is
likely that the same mechanism as in SRI discontin-
uation occurs in discontinuation of low-dose venla-
faxine and induces these unusual psychotic and
physicalsymptoms.
Drug manufacturers recommend gradual reduc-
tion of the dose of venlafaxine to prevent discontin-
uation syndrome. However, our patient shows that
unusual psychotic and physical symptoms (i.e. dis-
continuationsyndrome)canbeassociatedevenwith
discontinuation of a low dose of venlafaxine, even
when the discontinuation is gradual, and even when
combinedwithotherdrugs.Itisimportant,therefore,
toconsiderthatsomepatientsmayshowintolerance
toevenlow-dosevenlafaxine discontinuation.
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